Interactions between neuroticism and stressful life events predict response to pharmacotherapy for major depression: A CAN-BIND 1 report.
Timothy A Allen, Kate L Harkness, Raymond W Lam...
https://pubmed.ncbi.nlm.nih.gov/34008342/Actively Recruiting
Led by Nova Scotia Health Authority · Updated on 2026-06-11
400
Participants Needed
10
Research Sites
17 weeks
Total Duration
Researchers are evaluating a predictive biomarker algorithm designed to guide medication treatment for patients experiencing a major depressive episode within major depressive disorder MDD. This multi-site randomized study builds on data from a previous study and aims to integrate clinical, imaging, EEG, and molecular information to better predict treatment outcomes for participants. The study involves both patients with MDD and healthy controls to collect comprehensive data for analysis. Participants with MDD will be randomly assigned to one of two groups a Personalized Assignment group, where medication selection is guided by the biomarker algorithm, and a Random Assignment group, where medication is assigned without algorithm guidance. All patients receive open-label escitalopram 10-20 mg per day for 12 weeks. Depending on group and response prediction, participants may also receive blinded brexpiprazole 0.5-2 mg per day or placebo for the first 8 weeks, followed by an open-label phase of 4 weeks with medication adjustments based on treatment response. Over the 12-week period, participants attend seven study visits involving clinical assessments, cognitive tests, sample collections blood, urine, stool, neuroimaging MRI and EEG, and speech samples. The main outcome measure is the change in Montgomery Asberg Depression Rating Scale MADRS scores over the first 8 weeks. Researchers will use all collected data to identify features that best predict treatment response. Safety and clinical response will be monitored throughout the study with ongoing evaluations.
CONDITIONS
Optimized Predictive Treatment In Medications for Unipolar Major Depression (OPTIMUM-D)
J
Jessica B Toombs, MSc
N
Nicole M Stinson, BSc
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Nova Scotia Health Authority
Lead Sponsor
Unity Health Toronto
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 12 weeks
Participants receive open-label escitalopram and may receive either blinded brexpiprazole or placebo for the first 8 weeks. After 8 weeks, medication is adjusted based on treatment response, with some participants continuing brexpiprazole openly for 4 weeks and others continuing escitalopram alone.
7 visits
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
FACTORIAL
Primary Purpose
TREATMENT
Number of Arms
4
Have more questions? Get in touch with our team for quick support
Timothy A Allen, Kate L Harkness, Raymond W Lam...
https://pubmed.ncbi.nlm.nih.gov/34008342/Faranak Farzan, Sravya Atluri, Matthew Frehlich...
https://pubmed.ncbi.nlm.nih.gov/28785082/Shane J McInerney, Trisha Chakrabarty, Malgorzata Maciukiewicz...
https://pubmed.ncbi.nlm.nih.gov/33353384/Timothy A Allen, Raymond W Lam, Roumen Milev...
https://pubmed.ncbi.nlm.nih.gov/30220263/Katharine Dunlop, Sakina J Rizvi, Sidney H Kennedy...
https://pubmed.ncbi.nlm.nih.gov/32349119/Juan Pablo Lopez, Laura M Fiori, Cristiana Cruceanu...
https://pubmed.ncbi.nlm.nih.gov/28530238/Nikita Nogovitsyn, Meghan Muller, Roberto Souza...
https://pubmed.ncbi.nlm.nih.gov/31610545/Raymond W Lam, Roumen Milev, Susan Rotzinger...
https://pubmed.ncbi.nlm.nih.gov/27084692/Emma Morton, Venkat Bhat, Peter Giacobbe...
https://pubmed.ncbi.nlm.nih.gov/33860922/Giorgia Caspani, Gustavo Turecki, Raymond W Lam...
https://pubmed.ncbi.nlm.nih.gov/34294869/Nova Scotia Health Authority
Lead Sponsor
Unity Health Toronto
Collaborating Sponsor